SciLeads
SciLeads
Reports

BioPharma Funding – Q1 2026

Here’s a roundup of all the VC funding, and emerging companies, across biotech and pharma from January to March 2026.

SciLeads collates all scientific funding from VC and 1000s of academic sources – and provides contact details so you can act on it.

Sign up for our weekly newsletter here to get science funding news first. (You’ll get all of the below, but weekly as they happen, plus M&A, partnerships, post IPO debt/equity, RDOs, closures, and layoffs).

Jump to:

January 2026 Biopharma Funding

  • Biobeat (Tel Aviv, Israel) raised $50M in Series B funding to expand U.S. commercialization of its patch-worn, cuff-less 24-hour ambulatory blood pressure monitoring system. 
  • Vyriad (Rochester, MN, USA) raised $25M in Series B funding to advance its in vivo CAR T-cell therapy candidate VV169 into first-in-human clinical testing for relapsed or refractory multiple myeloma. 
  • Cellens (Cambridge, MA, USA) raised $6.5M in Series Seed funding to advance an AI- and mechanobiology-based, noninvasive bladder cancer test leveraging cellular biophysics and machine learning. 
  • Positron Corporation (Niagara Falls, NY, USA) raised $2M in funding to support commercial expansion, advance product development and regulatory activities, and grow its cardiac and oncology PET imaging business. 
  • Jaguar Health (San Francisco, CA, USA) received a $240K U.S. Food and Drug Administration Center for Veterinary Medicine grant to support an effectiveness study of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs. 
  • RheumaGen (Aurora, CO, USA) received Series A-1 funding to advance its HLA gene-editing program through early development toward a potential one-time gene therapy for celiac disease. 
  • Sinopia Biosciences (San Diego, CA, USA) received a National Institute of General Medical Sciences grant to advance development of its LEADS® data-driven drug discovery platform and expand metabolomics-enabled small-molecule screening capabilities. 
  • Parabilis Medicines (Cambridge, MA, USA) raised $305M in Series F funding to advance clinical development of its lead Helicon peptide FOG-001 across multiple tumor types and to expand its oncology pipeline and Helicon platform targeting historically undruggable proteins. 
  • Mirador Therapeutics (San Diego, CA, USA) raised $250M in Series B funding to advance its precision immunology pipeline and support rapid clinical development across immune-mediated diseases. 
  • Soley Therapeutics (South San Francisco, CA, USA) raised $200M in Series C funding to advance its cell stress sensing platform and progress first-in-class oncology programs into the clinic, including assets for AML and solid tumors. 
  • MEDIPOST (Cambridge, MA, USA) raised $140M in funding to support late-stage clinical development, including a planned U.S. Phase 3 trial of its mesenchymal stem cell therapy for knee osteoarthritis. 
  • Diagonal Therapeutics (Watertown, MA, USA) raised $125M in Series B funding to advance clinical development of its disease-modifying clustering antibody pipeline, led by DIAG723 for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
  • EpiBiologics (San Mateo, CA, USA) raised $107M in Series B funding to advance its pipeline of bispecific antibodies for selective extracellular protein degradation, including moving its lead EGFR-targeting program EPI-326 into first-in-human clinical trials in oncology. 
  • Kinaset Therapeutics (Boston, MA, USA) raised $103M in Series B funding to advance frevecitinib, an inhaled pan-JAK inhibitor, through Phase 2 clinical studies for severe asthma and other respiratory diseases. 
  • Rakuten Medical (San Diego, CA, USA) raised $100M in Series F funding to advance its Alluminox® platform-based photoimmunotherapy toward U.S. regulatory approval, including a global Phase 3 program for head and neck cancer. 
  • ViCentra (Utrecht, Netherlands) raised $98M in Series D funding to scale manufacturing, accelerate commercialization of its Kaleido insulin patch pump across Europe, and prepare its next-generation system for U.S. market access. 
  • Corsera Health (Boston, MA, USA) raised $80M in Series A funding to advance preventive RNAi medicines for cardiovascular disease, including a Phase 1 clinical program targeting PCSK9.
  • Mediar Therapeutics (Cambridge, MA, USA) raised $76M in Series B funding to advance its anti-fibrotic pipeline, including the Phase 2a development of MTX-474 for systemic sclerosis and Phase 1 studies of MTX-439 for chronic kidney disease–associated fibrosis. 
  • Beacon Therapeutics (London, United Kingdom) raised over $75M in Series C funding to advance its lead gene therapy laru-zova toward commercialization for X-linked retinitis pigmentosa and to accelerate development of its broader ocular disease pipeline. 
  • Spiro Medical (Irvine, CA, USA) raised $67M in Series A funding to develop a pulmonary neuromodulation system for the treatment of asthma. 
  • bit.bio (Cambridge, United Kingdom) raised $50M in Series C funding to scale its human cell programming platform, expand its product pipeline, and support growth into toxicology and AI-enabled drug discovery applications. 
  • Vizgen (Waltham, MA, USA) raised $48M in funding to advance its spatial multi-omics innovation roadmap, expand global researcher access, and scale manufacturing operations. 
  • Comanche Biopharma (Cambridge, MA, USA) raised $40M in funding to advance its siRNA-based therapy for preeclampsia, aiming to prolong pregnancy and reduce long-term health risks for mothers and babies.
  • Ventaris Surgical (San Carlos, CA, USA) raised $30M in Series A funding to advance development and clinical progress of its next-generation ureteroscopic system for more complete kidney stone treatment. 
  • Enable Injections (Cincinnati, OH, USA) raised $30M in funding to accelerate manufacturing capacity, strengthen its supply chain, and support commercial growth of its enFuse on-body drug delivery system. 
  • Enodia Therapeutics (Paris, France) raised $25M in seed funding to advance its machine-learning- and proteomics-enabled small-molecule platform for targeted protein degradation at the point of protein synthesis. 
  • Engitix Therapeutics (London, United Kingdom) raised $25M in a Series A extension to advance extracellular matrix–targeted therapeutics for solid tumors and fibrotic diseases. 
  • Nocion Therapeutics (Watertown, MA, USA) raised $23M in a Series B extension to support late-stage development of taplucainium for the treatment of chronic cough. 
  • Prudentia Sciences (Cambridge, MA, USA) raised $20M in Series A funding to expand its AI-native due diligence platform for life sciences dealmaking and to scale product development and commercial operations globally. 
  • TECregen (Basel, Switzerland) raised $12.6M in seed funding to advance thymus-rejuvenating biologics designed to restore immune function and promote long-term immune health. 
  • BrightHeart (Paris, France) raised $12M in Series A funding to scale its AI platform for prenatal ultrasound, supporting U.S. commercialization, European expansion, and continued product innovation. 
  • Find Therapeutics (Montreal, Canada) raised $10M in a Series A extension to support Phase 2–readiness activities for tasronetide, its lead remyelinating therapy for demyelinating diseases including multiple sclerosis. 
  • STRM.BIO (Cambridge, MA, USA) raised $8M in Series Seed 2 funding to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. 
  • Kenai Therapeutics (San Diego, CA, USA) received an $8M California Institute for Regenerative Medicine grant to advance its RNDP-001 allogeneic neuron replacement cell therapy for the treatment of idiopathic Parkinson’s disease through clinical development. 
  • Locus Biosciences (Morrisville, NC, USA) received a $3.3M NIH grant to support a Phase 1b clinical trial of its AI-designed bacteriophage therapy for treating hospital- and ventilator-associated pneumonia caused by antibiotic-resistant bacteria. 
  • Novoron Bioscience (San Diego, CA, USA) received a $2.5M NIH/NIA SBIR grant to accelerate Alzheimer’s drug discovery by developing and commercializing a human brain organoid screening platform to identify compounds that block tau propagation. 
  • Pramana Pharmaceuticals (Vancouver, Canada) received a $1M Alzheimer’s Association grant to support IND-enabling development of its first-in-class oral GPR119 agonist PRM-914 for Alzheimer’s disease. 
  • Muna Therapeutics (Copenhagen, Denmark) received a $1M Alzheimer’s Association grant to support its ongoing Phase 1 trial of the oral TREM2 agonist MNA-001 and to validate translational biomarkers to inform future Phase 2 studies in Alzheimer’s disease. 
  • Abbelight (Paris, France) raised an undisclosed amount in Series B funding to accelerate imaging innovation and scale adoption of its super-resolution microscopy solutions across biopharma, biotech, and research customers. 
  • Inquis Medical (Menlo Park, CA, USA) raised $75M in Series C funding to scale nationwide commercial adoption of its AVENTUS thrombectomy system and advance its next-generation product pipeline. 
  • Oricell Therapeutics (Shanghai, China) raised $70M in Series C funding to accelerate global clinical development and commercialization of its solid tumor CAR-T cell therapy pipeline. 
  • Vibrant Therapeutics (Guangzhou, China) raised $61M in funding to advance its logic-gated solid tumor pipeline, expand global development activities, and scale its next-generation drug design platform.
  • Cytotheryx (Rochester, MN, USA) raised $60M in closing of a ~$9.3MSeries A funding to advance its liver cell therapy programs into the clinic and scale GMP manufacturing and operational capacity. 
  • Positive Development (McLean, VA, USA) raised up to $45M in funding to support nationwide expansion of developmental therapy and autism diagnostics services, pursue acquisitions, and increase access to care for autistic children and their families.
  • Trailhead Biosystems (Beachwood, OH, USA) raised $40M in funding to accelerate commercialization of its iPSC-derived human cell and media products and scale manufacturing and operational capabilities. 
  • Juvena Therapeutics (Redwood City, CA, USA) raised $33.5M in Series B funding to advance its regenerative biologics pipeline and expand clinical development and AI-enabled discovery capabilities. 
  • Converge Bio (Tel Aviv, Israel) raised $25M in Series A funding to expand its generative AI platform for accelerating drug discovery and development across biotech and pharmaceutical companies. 
  • Nuclera (Cambridge, United Kingdom) raised an additional $12M to extend its Series C funding to $87M to advance antibody engineering capabilities within its eProtein Discovery platform. 
  • Enspire DBS Therapy (Cleveland, OH, USA) raised $10.3M in Series B1 funding to advance pivotal clinical development of its deep brain stimulation–enabled rehabilitation therapy for post-stroke recovery. 
  • AI4Eyes (Montréal, Canada) raised $6.5M in funding to advance regulatory approvals, expand clinical programs, and support commercialization of its AI-powered eye care solutions. 
  • Nanochon (Washington, DC, USA) raised $4.1M in seed funding to support its first-in-human clinical study for its knee cartilage repair implant and advance R&D and trial planning.
  • OutSee (Cambridge, United Kingdom) raised $3.2M in seed funding to advance AI-driven genomic target discovery and progress its lead drug discovery programme toward therapeutic development. 
  • Axol Bioscience (Cambridge, United Kingdom) raised $2.8M in funding to support expansion of its US operations, advance product development, and scale up iPSC cell manufacturing. 
  • MeMed (Haifa, Israel) received a $2M Israel Innovation Authority grant to establish an acute-care digital and physical biobank to accelerate the development and validation of AI-enabled diagnostics for high-risk patients. 
  • Synchrony Medical (Jersey City, NJ, USA) raised $1M in funding to scale U.S. commercialization of its LibAirty airway clearance system, while supporting ongoing clinical research, product development, and expanded patient access nationwide. 
  • PulseAI (Belfast, United Kingdom) raised an undisclosed amount in seed funding to scale deployment of its AI-driven ECG diagnostics platform and advance clinical validation and U.S. FDA 510(k) clearance. 
  • Invictus Therapeutics (Warwick, RI, USA) received an undisclosed Breakthrough T1D grant to support a first-in-human clinical trial of its next-generation ultra-rapid insulin analog for automated insulin delivery systems. 
  • MAUI Imaging (San Jose, CA, USA) received a Gates Foundation grant to evaluate computed echo tomography ultrasound as a tool for the detection, diagnosis, and triage of tuberculosis in resource-limited settings. 
  • Crosswalk Therapeutics (Cambridge, MA, USA) received a National MPS Society research grant to support early development of a next-generation enzyme-based therapy for Mucopolysaccharidosis IVA (Morquio A syndrome).
  • CORXEL (Berkeley Heights, NJ, USA) raised $287M in Series D1 funding to advance its cardiometabolic pipeline, led by development of CX11, an oral small-molecule GLP-1 receptor agonist progressing through U.S. and global Phase 2 trials, alongside additional programs for obesity, diabetes, stroke, and hypertension. 
  • PAQ Therapeutics (Burlington, MA, USA) raised $77M in Series B funding to advance its KRAS-targeted protein degradation pipeline, including Phase 1 clinical development of its pan-KRAS degrader PT0511 and KRAS G12D degrader PT0253. 
  • Exciva (Heidelberg, Germany) raised $55M in Series B funding to advance its lead Alzheimer’s therapy Deraphan into a Phase 2 clinical trial for agitation associated with Alzheimer’s disease. 
  • Think Bioscience (Boulder, CO, USA) raised $55M in Series A funding to advance its internal pipeline of first-in-class small-molecule programs targeting historically difficult drug targets, including a lead program for Noonan syndrome. 
  • L-Nutra (Los Angeles, CA, USA) raised $36.5M in Series D funding to accelerate global expansion of its longevity and medical nutrition therapies, including launching a joint venture in Abu Dhabi to support healthy aging and disease remission across the MENA region.
  • Infinitopes (Oxford, United Kingdom) raised $35M in seed funding to advance clinical development of its precision cancer vaccine platform, including launching a first-in-human Phase I/IIa trial of its lead candidate aimed at preventing oesophageal cancer recurrence. 
  • BIOMAKERS (San Francisco, CA, USA) raised $8M in funding to scale its AI-native precision oncology intelligence platform and expand global molecular diagnostics and clinical data infrastructure. 
  • Juniper Biomedical (Worcester, MA, USA) received a $2.9M NIH SPARC Neuromod Prize grant to support product development and clinical trials of its neuromodulation micro-implant for treating mixed urinary incontinence and other pelvic health disorders. 
  • Neuropacs (Gainesville, FL, USA) raised $1M in seed funding to expand development and prepare for clinical commercialization of its AI-driven neurological diagnostics platform. 
  • Crosswalk Therapeutics (Boston, MA, USA) received a National MPS Society grant to support early development of a next-generation enzyme-based therapy designed to address skeletal disease in patients with Morquio A syndrome.

January 2026 Emerging Biopharma Companies

  • Addition Therapeutics (South San Francisco, CA, USA) emerged from stealth with $100M in funding to advance an all-RNA, non-viral LNP-based genomic medicine platform for the development of durable, one-time therapies targeting chronic and rare diseases. 
  • Mitera Biosciences (Bellevue, WA, USA) emerged from stealth with $1.75M in seed funding to advance a platform translating pregnancy-derived immune tolerance biology into preclinical therapies for autoimmune diseases and organ transplant rejection.
  • NeurAeon Technologies (Kansas City, MO, USA) launched to develop pharmaceutical-grade neural enhancement systems aimed at safely amplifying memory, focus, creativity, and cognitive resilience through advanced nanoparticle delivery and quantum-biological interfaces.. 
  • Metavalis Inc. (Missouri, USA) emerged from stealth to build sovereign infrastructure at the intersection of national defense and synthetic biology, focused on re-dosable genetic medicines, military-grade AI compute, and secure biotech platforms.
  • AirNexis Therapeutics (Palo Alto, CA, USA) launched with $200M in Series A funding to advance global Phase 2 development of its dual PDE3/4 inhibitor AN01 for chronic obstructive pulmonary disease (COPD). 
  • Alveus Therapeutics (Philadelphia, PA, USA) launched with $160M in Series A funding to advance next-generation therapies for obesity and metabolic diseases, including Phase 2 development of its lead bifunctional GIPR antagonist/GLP-1R agonist and progression of an amylin-based pipeline. 
  • SonoThera (South San Francisco, CA, USA) launched with $125M in Series B funding to advance multiple nonviral genetic medicine programs toward first-in-human clinical studies using its ultrasound-mediated delivery platform. 
  • Edison Scientific (San Francisco, CA, USA) emerged from stealth with $70M in seed funding to build an AI “scientist” platform designed to automate literature synthesis, data analysis, experiment planning, and molecule or materials design. 
  • Poplar Therapeutics (Boston, MA, USA) launched with $50M in Series A funding to advance a new class of anti-IgE therapies for food allergy and other atopic conditions. 
  • 32 Biosciences (North Chicago, IL, USA) launched with $40M in Series A funding to advance its lead mucosal-immune modulator CS-0003 through Phase II for gastrointestinal surgical site infections and to expand its GI mucosal-immune pipeline and metabolomics-driven discovery platform. 
  • Aurora Therapeutics (San Francisco, CA, USA) launched with $16M in seed funding to build a scalable personalized gene-editing platform aimed at treating rare genetic mutations that have historically been impractical to address at scale. 
  • Topos Bio (USA) emerged from stealth with $10.5M in seed funding to develop an AI-driven platform for targeting intrinsically disordered proteins, opening new therapeutic opportunities across neurodegenerative diseases and cancer. 
  • HoX Bio (Los Angeles, CA, USA) emerged from stealth with a $2M pilot to deploy its integrated platform for autonomous, digital lab workflows in support of next-generation biosecurity and early biological threat detection applications.
  • Klona Biotech (London, United Kingdom) emerged from stealth with $1.4M in pre-seed funding to develop decentralized manufacturing systems for personalized, regenerative medical implants. 
  • 3C Therapeutics (Vancouver, Canada) launched to develop a next-generation modular degrader–antibody conjugate platform for targeted protein degradation
  • Syrna Therapeutics (San Diego, CA, USA) emerged from stealth to advance structure-guided drug discovery targeting mRNA, including the rational design of small-molecule covalent translation inhibitors. 
  • Agni Bio (South San Francisco, CA, USA) emerged from stealth to build a best-in-class pipeline focused on delivering transformational therapies for solid tumors and autoimmune diseases
  • Caldera Therapeutics (Cambridge, MA, USA) launched with $112.5M in Series A and Series A-1 funding to advance a first-in-class bispecific antibody for inflammatory bowel disease, with its lead program CLD-423 entering Phase 1 clinical testing. 
  • Proxima (New York, NY, USA) emerged from stealth with $80M in seed funding to develop AI-designed proximity-based “molecular matchmaker” drugs that reprogram protein interactions to treat disease. 
  • Vivere Oncotherapies (Berkeley, CA, USA) emerged from stealth with over $10M in seed funding to develop next-generation cancer therapies designed to activate the immune system and unmask immunologically cold tumors. 
  • Tahoe Therapeutics (San Francisco, CA, USA) and Alloy Therapeutics (Boston, MA, USA) are joining to create a new company (South San Francisco, CA, USA) to develop first-in-class antibody-drug conjugates targeting hard-to-treat cancers. 
  • Modunai Therapeutics (Mansfield, MA, USA) is operating in stealth to advance next-generation bispecific immunotherapies for therapy-resistant, immunologically cold, and checkpoint-refractory solid tumors.
  • Mendra (San Francisco, CA, USA) launched with $82M in Series A funding to acquire, develop, and commercialize rare disease therapeutics, using AI to accelerate asset selection, clinical development, and global patient access. 
  • Resolve M Therapeutics (Cambridge, MA, USA) emerged from stealth to advance a first-of-its-kind pro-resolution platform designed to restore immune homeostasis by engaging the body’s innate mechanisms, with the goal of treating chronic inflammatory and autoimmune diseases. 

February 2026 Biopharma Funding

  • Cellares (South San Francisco, CA, USA) raised $257M in Series D funding to scale automated cell therapy manufacturing and support global commercial launch through expansion of its Smart Factory network. 
  • TRexBio (South San Francisco, CA, USA) raised $50M in funding to support clinical development of its tissue-targeted Treg therapeutics, including advancing its lead TNFR2 agonist in inflammatory diseases and progressing additional immunology programs toward the clinic. 
  • Primmune Therapeutics (San Diego, CA, USA) raised $23.3M in Series B funding to advance clinical development of its oral TLR7 agonist PRTX007, including a Phase 2 neoadjuvant study in melanoma. 
  • 1st Biotherapeutics (Seoul, South Korea) raised $22M in Series D funding to accelerate clinical development of its HPK1 inhibitor program while advancing additional neurodegenerative and immuno-oncology pipelines. 
  • Prenosis (Chicago, IL, USA) raised $20M in Series A funding and received a $20M BARDA grant to support commercial deployment of its AI-based diagnostics, advance clinical and regulatory programs, and expand its precision medicine platform for critical care conditions including sepsis and respiratory disease. 
  • CraniUS Therapeutics (Baltimore, MD, USA) raised $20M in Series B funding to advance its NeuroPASS™ implantable platform toward regulatory progress, manufacturing scale-up, and future commercialization for direct drug delivery to the brain. 
  • PranaX Corporation (Houston, TX, USA) raised $17M in Series A funding to advance development of exosome-based regenerative biologics, expand R&D and infrastructure, and support product development and commercialization efforts. 
  • 4baseCare (Bengaluru, India) raised $9.8M in Series B funding to expand its hospital-linked genomics laboratory network and scale precision oncology services across emerging markets. 
  • Barnwell Bio (New York, NY, USA) raised $6M in Seed funding to scale its metagenomic biosurveillance platform for early detection of disease threats across the poultry supply chain. 
  • Bexorg (New Haven, CT, USA) received a Michael J. Fox Foundation grant to identify translational biomarkers supporting TRPML1-targeted Parkinson’s disease therapies. 
  • CytoDyn (Vancouver, WA, USA) raised an undisclosed in funding to support an Expanded Access Program providing leronlimab to patients with triple-negative breast cancer. 
  • Stellular Bio (Watertown, MA, USA) raised an undisclosed in amount Series 1 funding to advance its platelet-derived regenerative biologic therapy into clinical testing for Sjögren’s disease dry eye and other ocular surface diseases. 
  • Angitia Biopharmaceuticals (Westlake Village, CA, USA) raised $130M in Series D funding to advance the clinical development of its musculoskeletal disease pipeline, including programs for osteoporosis, osteogenesis imperfecta, and spinal fusion. 
  • AccurEdit Therapeutics (Suzhou, China) raised $75M in funding to advance gene editing therapies across ATTR, PCSK9, and MASH/NASH indications. 
  • Deep Intelligent Pharma (China) raised $60M in funding to upgrade its AI-driven full-stack clinical trial intelligence platform and advance autonomous drug development capabilities. 
  • Biorce (Barcelona, Spain) raised $52M in Series A funding to accelerate AI-driven clinical trial development, support international expansion, and scale its clinical trial intelligence platform. 
  • Third Arc Bio (Spring House, PA, USA) raised $52M in a Series A extension to expand its oncology and immunology & inflammation portfolio and advance additional programs into the clinic. 
  • Pinwheel Therapeutics (Mumbai, India) raised $20M in funding to advance late-stage clinical development of Ciraparantag, a universal anticoagulant reversal therapy for emergency and acute-care settings. 
  • Stratus Medical (Magnolia, TX, USA) raised $10M in Series B funding to complete development of its radiofrequency ablation technologies and fund a clinical trial for chronic pain treatment. 
  • NuVision Biotherapies (Nottingham, United Kingdom) raised $6M in funding to expand operations and advance development of its tissue-therapy products for ophthalmology applications. 
  • HemostOD (Lausanne, Switzerland) received a $2.5M Innosuisse grant to advance the preclinical development of its donor-free, off-the-shelf universal platelet manufacturing platform. 
  • Imbed Biosciences (Middleton, WI, USA) raised an undisclosed amount in strategic funding to expand its U.S. market presence and accelerate development of its SAM™ antimicrobial wound care technology platform. 
  • Ecovia Bio (Grosse Pointe, MI, USA) raised an undisclosed amount in Series B funding to expand manufacturing capacity for its biodegradable gamma polyglutamic acid biopolymer products. 
  • Eurofins CDMO Alphora (Mississauga, Canada) received an undisclosed National Research Council of Canada Industrial Research Assistance Program grant to develop a high-yield expression platform aimed at simplifying and accelerating next-generation antibody-drug conjugate manufacturing/ 
  • ILiAD Biotechnologies (Weston, FL, USA) raised $115M in Series B funding to support Phase 3 development of its intranasal pertussis vaccine candidate BPZE1, with a pivotal human challenge study planned for 2026. 
  • Loyal (San Francisco, CA, USA) raised $100M in Series C funding to advance regulatory approval and commercial launch of LOY-002, its lead drug candidate aimed at extending the healthy lifespan of senior dogs. 
  • QuantX Biosciences (Princeton, NJ, USA) raised $85M in Series B funding to advance clinical development of its oral STAT6 and IL-17 small molecule inhibitors and to expand discovery efforts in immunology and inflammation. 
  • Neurent Medical (Galway, Ireland) raised $74M in Series C funding to accelerate commercial expansion of its NEUROMARK® system for chronic rhinitis, expand clinical evidence generation, and advance its product and indication pipeline. 
  • Regend Therapeutics (Shanghai, China) raised ~$49M in Series C funding  to advance clinical development of its progenitor cell therapies for lung and kidney diseases, expand manufacturing capacity, and support commercialization and international expansion.
  • Aerska (Dublin, Ireland) raised $39M in Series A funding to advance its brain shuttle antibody-oligo conjugate platform and support clinical development of systemically delivered RNA interference therapeutics for neurological diseases. 
  • Galux (Seoul, South Korea) raised $29M in Series B funding to advance its AI-driven de novo protein design platform, expand R&D infrastructure, and accelerate preclinical development of its proprietary therapeutic pipelines. 
  • OncoRes Medical (Perth, Australia) raised $27M in private funding to advance clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™, including supporting its Australian clinical trial and preparing for a U.S. pivotal trial. 
  • Kainova Therapeutics (Strasbourg, France) raised $23M in Series B funding to advance clinical development of its GPCR-targeting therapies for immuno-oncology and inflammatory diseases, including its lead anti-CCR8 antibody program. 
  • Pandorum Technologies (Bengaluru, India) raised $18M in Series B funding to advance clinical development of its programmable exosome-based regenerative therapies, including Kuragenx, and to expand global manufacturing and market access across the U.S., Asia, and the Middle East. 
  • 4Moving Biotech (Lille, France) raised $13M in funding to advance its first-in-class disease-modifying osteoarthritis drug for knee osteoarthritis through Phase 2a and toward proof-of-concept. 
  • Exact Imaging (Toronto, Canada) raised $10M in funding to accelerate global commercial expansion and drive adoption of its ExactVu™ micro-ultrasound prostate biopsy system. 
  • Berlin Heals Holding AG (Zug, Switzerland) raised over $10M in funding to advance its cardiac microcurrent technology, expand clinical research, develop less invasive implantation techniques, and initiate larger double-blinded trials in preparation for FDA IDE submission. 
  • Gyala Therapeutics (Barcelona, Spain) received a $4M grant from Spain’s Ministry of Science, Innovation and Universities to support a Phase I/IIa clinical trial of its CD84-targeting CAR-T therapy, GYA01, in relapsed or refractory acute leukemias. 
  • Sable Bio (London, United Kingdom) raised $3.75M in seed funding to scale its AI-driven drug safety platform, expand its team, accelerate product development, and integrate real-world evidence to support earlier identification of safety risks in drug discovery. 
  • ArrayPatch (Cork, Ireland) raised $3.2M in seed funding to advance its ITZ-DerMap™ microneedle patch for the treatment of onychomycosis toward clinical proof-of-concept. 
  • Entirety Biomedical (Detroit, MI, USA) raised $1.2M in seed funding to advance development of its absorbable magnesium orthopedic implant systems toward first-in-human clinical trials. 
  • Humacyte (Durham, NC, USA) received a grant from the U.S. Department of Defense to support procurement and evaluation of its FDA-approved bioengineered blood vessel, Symvess®, for the treatment of traumatic vascular injuries in military personnel. 
  • Cosomil (Tokyo, Japan) raised an undisclosed amount in Series A1 funding to accelerate development and deployment of its single-molecule enzyme activity-based liquid biopsy tests for early cancer detection in Japan and the US, including regulatory preparation for its pancreatic cancer screening assay. 
  • Postbiotics, Inc. (Winston-Salem, NC, USA) received a strategic investment from Wake Forest University School of Medicine to support commercialization of its patented postbiotic strain D3.5 and the upcoming launch of its Gutibio™ medical food product.
  • Altesa BioSciences (Atlanta, GA, USA) raised $75M in Series B funding to advance clinical development of its oral antiviral respiratory therapy, including supporting a Phase 2b study aimed at preventing serious respiratory infections. 
  • ProSomnus Sleep Technologies (San Francisco, CA, USA) raised up to $38M in strategic funding to expand its technology-enabled sleep health platform, advance next-generation remote patient monitoring and proprietary diagnostic devices, fund comparative clinical studies, and scale infrastructure to support growing demand for non-CPAP obstructive sleep apnea therapies. 
  • GE HealthCare (Chicago, IL, USA) received approximately $35M in funding from BARDA to advance development of artificial intelligence-powered ultrasound technologies and new point-of-care platforms to support trauma assessment and emergency preparedness in mass casualty settings. 
  • Starget Pharma (Shreveport, LA, USA) raised $18M in Series A funding to advance its AI-enabled radioligand therapy pipeline into clinical development, expand U.S. translational and manufacturing capabilities, and progress its lead SSTR3-targeted theranostic programs for cancer. 
  • GelMEDIX (Cambridge, MA, USA) raised $13M in seed funding to advance its lead retinal pigment epithelial cell therapy program for Geographic Atrophy and further develop its injectable hydrogel scaffold platform to enhance delivery and performance of cell and gene therapies. 
  • Levee Medical (Durham, NC, USA) raised over $12M in funding to support its PMA submission process and advance the ARID II pivotal trial evaluating its Voro® Urologic Scaffold in men undergoing prostate cancer surgery. 
  • Herantis Pharma (Espoo, Finland) received an $8.7M Horizon Europe grant to support a Phase 2 proof-of-concept trial of HER-096 in early-stage Parkinson’s disease, funding execution of the randomized, placebo-controlled study. 
  • Peptris Technologies (Bengaluru, India) raised ~$8.4M in Series A funding to advance its AI-led drug discovery programs toward clinical readiness and expand its pipeline of novel chemical entities and repurposing assets.
  • Neogap Therapeutics (Stockholm, Sweden) raised $8.2M in funding to advance its ongoing first-in-human clinical trial of its personalised T-cell therapy for advanced colorectal cancer and to generate data supporting the next stage of development. 
  • Tozaro (Bedford, United Kingdom) raised $7.5M in funding to advance its Smart Polymer platform aimed at lowering production costs for cell and gene therapies, support new commercial partnerships, and expand development of its manufacturing technology for viral vectors including lentiviral and AAV systems. 
  • Synchrony Medical (Jersey City, NJ, USA) raised $5M in funding to accelerate U.S. commercial expansion of its FDA-cleared LibAirty™ at-home airway clearance system, support ongoing clinical research and product development, and broaden patient access for chronic respiratory disease. 
  • Neupulse (Nottingham, United Kingdom) raised ~$3.8M  to scale sales, advance regulatory progress, and support commercial launch of its non-drug neurotherapeutic wristband device for Tourette Syndrome.
  • Step Pharma (Saint-Genis-Pouilly, France) received a $2.7M EIC Accelerator grant, with potential for up to $10.8M in equity investment, to advance its CTPS1 inhibitor dencatistat into Phase 1b expansion cohorts for CTPS2 null ovarian and endometrial cancers and prepare for Phase 2 development in gynaecological tumours. 
  • Lario Therapeutics (Edinburgh, United Kingdom) received $2.4M in grant funding from The Michael J. Fox Foundation and Wellcome to expand its neuronal calcium channel drug discovery platform into Parkinson’s disease and post-traumatic stress disorder, advancing selective small-molecule programmes targeting CaV1.3 and CaV2.3. 
  • Seek Labs (Salt Lake City, UT, USA) received a $2M U.S. Department of Agriculture grant to develop a mutation-resistant, CRISPR-based therapeutic targeting highly pathogenic avian influenza using its programmable disease response platform. 
  • Elumn8 Medical (Campbell, CA, USA) raised funding in an initial close of its Series C round to advance clinical development of its Acolyte™ image-guided coronary CTO platform, which is being evaluated in a pre-market trial for chronic total occlusions. 
  • Marvel Biosciences (Calgary, Canada) received funding from the National Research Council of Canada Industrial Research Assistance Program to develop a pediatric-friendly liquid formulation of its lead compound MB-204 for neurodevelopmental disorders, including autism spectrum disorder, Rett syndrome, and Fragile X syndrome. 
  • Ten63 Therapeutics (Durham, NC, USA) raised an undisclosed amount in funding to advance its AI-driven BEYOND drug discovery platform and progress small molecule programs targeting oncology and viral diseases, including HPV-related cancers. 
  • Leon Nanodrugs (Munich, Germany) raised an undisclosed amount to accelerate global commercialization of its lipid nanoparticle manufacturing systems and scale production capabilities for RNA-based and advanced therapies.
  • AAX Biotech (Stockholm, Sweden) raised an undisclosed amoun to advance and scale its Seqitope® and Opti-mAb® antibody discovery platforms and expand collaborations in antibody-based drug development.

 

February 2026 Emerging Biopharma Companies

  • Breakthru Medicine (Phoenix, AZ, USA) emerged from stealth with $60M in Series A funding to develop novel cancer therapeutics across multiple modalities, including small molecules, molecular glues, and next-generation antibody–drug conjugate payloads. 
  • Fortitude Biomedicines (Waltham, MA, USA) launched with $13M in Seed funding to advance immune cell-targeting antibody therapies and a proprietary molecular glue–enabled ADC platform for autoimmune diseases and cancer. 
  • Kalyx Labs (London, United Kingdom) emerged from stealth to advance its biotech platform following a focused, validation-driven development phase ahead of public market entry.
  • AllerGene AI Therapeutics (Miami, FL, USA) emerged from stealth to develop first-in-class in vivo mRNA-LNP CAR-T therapies targeting mast cells for severe allergies and anaphylaxis prevention.
  • Phylo (San Francisco, CA, USA) emerged from stealth with $13.5M in seed funding to launch an AI-powered scientific assistant designed to support and automate biomedical research workflows.
  • ALTx Therapeutics (London, United Kingdom) emerged from stealth with $17.1M in funding to develop small-molecule therapies targeting the alternative lengthening of telomeres (ALT) pathway in cancer. 
  • Vesalic Limited (London, United Kingdom) emerged from stealth to advance a novel therapeutic targeting a systemic metabolic driver of motor neuron diseases, including ALS, and to develop a blood-based biomarker platform for early diagnosis of ALS and other neurodegenerative diseases. 
  • Cubase Bio (Stockholm, Sweden) is operating in stealth to develop next-generation 3D spatial transcriptomics technologies for complex tissue structures. 
  • Absco Therapeutics (Boston, MA, USA) is operating in stealth to advance immune engineering therapeutics emerging from collaborations between clinicians at MGH and BWH and engineers at MIT.
  • Korsana Biosciences (Waltham, MA, USA) emerged from stealth with $175M in funding to advance potential best-in-class therapeutics for neurodegenerative diseases, including its lead amyloid beta-targeting antibody program for Alzheimer’s disease. 
  • DeckBio (Boston, MA, USA) is operating in stealth while advancing T cell receptor (TCR)-based therapies designed to target intracellular cancer antigens, aiming to address the ~75% of cancer-driving proteins that are inaccessible to traditional antibody-based treatments. 
  • Hijack Bio (London, United Kingdom) is operating in stealth to develop environmentally responsive, targeted biogenic drug delivery systems, delivering a bespoke platform for next-generation biotherapeutic delivery.

 

March 2026 Biopharma Funding

  • Alveus Therapeutics (Copenhagen, Denmark) raised $197M in Series A funding to advance clinical development of its next-generation obesity and metabolic disease therapies, including ALV-100 and ALV-200, and to progress its oral amylin program toward first-in-human studies. 
  • Emergent BioSolutions (Gaithersburg, MD, USA) received $140M in funding to deliver medical countermeasures supporting Canada’s biological threat preparedness and long-term stockpiling strategy. 
  • BreezeBio (South San Francisco, CA, USA) raised $60M in Series B funding to advance its internal pipeline of precision genetic medicines, including BRZ-101 for type 1 diabetes, into IND-enabling studies and to expand its NanoGalaxy® delivery platform. 
  • Turbine (Budapest, Hungary) raised $25M in Series B funding to broaden its virtual biology platform, enabling the virtualization of additional assays across drug discovery and translational medicine. 
  • Linnaeus Therapeutics (Haddonfield, NJ, USA) received a $22M ARPA-H grant to advance its lead candidate LNS8801 for healthspan preservation and the prevention of age-related functional decline. 
  • Syndex Bio (Cambridge, United Kingdom) to raise $15.5M in seed financing to advance its mcPCR technology following its unveiling at AGBT 2026. This funding supports the company’s development and commercialization of next generation molecular diagnostics. This investment enables further scaling of its platform and expansion of operations.
  • Ethris (Munich, Germany) received a $14M European Commission grant to advance its mRNA-based mucosal vaccine candidate for pandemic influenza into Phase 1 clinical development, as part of the NOFLU consortium. 
  • Tamarind Bio Inc. (San Francisco, CA, USA) to raise $13.6M in Series A financing to make AI more accessible for biology. This funding supports the expansion of its AI driven tools designed to accelerate biological research and drug discovery. This investment enables product development and team growth.
  • BrainCheck (Austin, TX, USA) raised $13M in Series A funding to expand its AI-enabled cognitive care platform, enhance workflow integration and scale longitudinal cognitive assessment across enterprise healthcare settings. 
  • Abram Scientific (San Francisco, CA, USA) raised $11.75M in Series A funding to accelerate development of its portable CoagCare™ coagulation diagnostics platform and advance the system toward FDA 510(k) clearance and clinical milestones. 
  • Avisi Technologies (Redwood City, CA, USA) raised $10.7M in Series A funding to support its SAPPHIRE pivotal trial and advance development of its VisiPlate® glaucoma device pipeline. 
  • Centauri Therapeutics (Alderley Park, United Kingdom) raised $7.5M in Series A funding to support Phase I clinical development of its lead antimicrobial candidate CTX-187 and advance preparations for Phase II studies.
  • Brainomix (Oxford, United Kingdom) raised $6.5M in Series C funding to support U.S. expansion and accelerate deployment of its AI-powered imaging platforms for stroke and lung fibrosis.
  • Basilea (Allschwil, Switzerland) received a $6M BARDA grant to continue development of its oral antibiotic ceftibuten-ledaborbactam for the treatment of complicated urinary tract infections, including preparation for Phase 3 clinical trials. 
  • Blue Arbor Technologies (Grass Lake, MI, USA) raised $5M in Series A funding to advance clinical validation and commercialization of its RESTORE™ Neuromuscular Interface System for intuitive prosthetic control. 
  • Citius Pharmaceuticals (Cranford, NJ, USA) received $3.8M from the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer Program to support commercial execution and advance its late-stage pipeline programs.
  • ATRO Medical B.V. (Eindhoven, Netherlands) to raise $3M to advance its artificial meniscus toward pivotal studies. This funding supports clinical development and regulatory preparation for its implant technology. This investment progresses the company toward key clinical milestones.
  • D-Sight (Barcelona, Spain) raised $2.2M in funding to advance its neuroprotective eye-drop therapies for diabetic retinopathy and glaucoma, supporting early clinical development and preparation for further trials. 
  • Myrias Optics Inc. (Montreal, Canada) to raise $2.1M in Seed 1 financing to accelerate commercialization of its wafer level metaoptics technology. This funding supports scaling manufacturing capabilities and bringing advanced optical solutions to market. This investment advances its product development and customer expansion efforts.
  • Baxiva (Zurich, Switzerland) received a $150K Venture Kick grant to advance development of its first-in-class glycoconjugate vaccine targeting Escherichia coli, aimed at preventing infections and reducing antibiotic resistance and related complications such as sepsis. 
  • Baio Labs (Zurich, Switzerland) received a $40K Venture Kick grant to further develop its generative AI platform, Drugon, for structure-based molecular design and to accelerate the productionization and scaling of the technology.
  • Clee Medical (Geneva, Switzerland) raised Seed funding to advance its real-time intraoperative imaging platform for brain surgery, supporting clinical studies, product development and regulatory progress toward commercialization.
  • Cognito Therapeutics (Cambridge, MA, USA) raised $105M in Series C funding to advance development of its Spectris neurostimulation therapy for Alzheimer’s disease and support regulatory submission and commercialization preparations. 
  • QL Biopharm (Beijing, China) raised $72M in funding to advance clinical development of its metabolic disease pipeline, including a once-monthly GLP-1 injectable for obesity and diabetes currently in Phase 3. 
  • ZhiTai Biotech (Beijing, China) raised $70M in Series C funding to advance the clinical development of long-acting and oral peptide therapies for obesity and other metabolic diseases. 
  • Polares Medical (Lausanne, Switzerland) raised $50M in Series C funding to advance clinical studies and support U.S. expansion of its MRace Posterior Leaflet Replacement system for mitral regurgitation. 
  • Poplar Therapeutics (Cambridge, MA, USA) raised $45M in Series A extension funding to advance clinical development of its anti-IgE therapy PHB-050 for food allergy and other atopic conditions. 
  • Atavistik Bio (Cambridge, MA, USA) raised $40M in Series B funding to advance clinical development of its AKT1-selective inhibitor ATV-1601 for hereditary hemorrhagic telangiectasia and progress its JAK2 V617F inhibitor program for myeloproliferative neoplasms through clinical proof of concept. 
  • Leman Bio (Shanghai, China) raised $28M in funding to advance clinical development of metabolism-enhanced CAR-T cell therapies for hematological cancers, solid tumors, and autoimmune diseases. 
  • Transposon Therapeutics (San Diego, CA, USA) received up to $22M in ARPA-H grant funding to evaluate its LINE-1 reverse transcriptase inhibitor TPN-101 for extending healthy aging. 
  • Minnesota Medical Technologies (Stewartville, MN, USA) raised $20.6M in Series A funding to support the U.S. commercial launch of its StaySure device for managing fecal incontinence and to scale operations. 
  • KangaBio (Hangzhou, China) raised $15M in Pre-A+ funding to advance the clinical development of its oncology prodrug pipeline. 
  • Seaport Therapeutics (Boston, MA, USA) received up to $15M in ARPA-H grant funding to advance development of its oral therapeutic GlyphCele designed to restore gut lymphatic function for metabolic disease and pancreatic cancer. 
  • Ticairus (Seoul, South Korea) raised $14.8M in Series D funding to advance clinical development of its CAR-T cell therapies for blood cancers and solid tumors. 
  • Antiverse (Cardiff, United Kingdom) raised $9.3M in Series A funding to expand its AI-driven antibody design platform and advance internal therapeutic antibody programs toward in vivo studies. 
  • Antheia (Menlo Park, CA, USA) received an additional $9M BioMaP Consortium grant to support domestic manufacturing of critical pharmaceutical ingredients and strengthen U.S. drug supply chains. 
  • Alithea Genomics (Lausanne, Switzerland) raised $8.9M in seed funding to scale industrial-level RNA sequencing technology for primary drug screening and toxicology. 
  • Egle Therapeutics (Paris, France) received an $8.7M Horizon Europe grant to support the clinical development of EGL-001 and advance translational research in neoadjuvant head and neck cancer. 
  • Theolytics (Oxford, United Kingdom) received an $8.7M Horizon Europe grant to support a Phase 2 study of its oncolytic immunotherapy THEO-260 in platinum-resistant ovarian cancer. 
  • Oncodesign Precision Medicine (Dijon, France) received a $6.9M Michael J. Fox Foundation grant to support preparation of clinical drug product and advance development of its LRRK2 inhibitor OPM-201 for Parkinson’s disease. 
  • Genflow Biosciences (Gosselies, Belgium) received a $4.3M Wallonia Region grant to support development of its gene therapy candidate GF-1002 for MASH. 
  • Syantra (Calgary, Canada) received a $2.4M U.S. Department of Defense grant to support development and clinical validation of its Onco-ID blood test designed to detect breast cancer through immune-response gene expression signals. 
  • Spinogenix (Los Angeles, CA, USA) received an undisclosed FRAXA Research Foundation grant to support site principal investigators conducting a Phase 2b trial of its investigational Fragile X syndrome therapy SPG601. 
  • Inventage Lab (Seoul, South Korea) raised $74M in funding to accelerate commercialization of its long-acting injectable drug delivery platforms and expand GMP manufacturing capacity. 
  • Vitestro (Utrecht, Netherlands) raised $70M in Series B funding to advance its Aletta autonomous robotic phlebotomy device, support FDA regulatory activities, and scale manufacturing and commercial operations for global deployment.
  • Vima Therapeutics (Cambridge, MA, USA) raised $40M in Series A funding, extending the round to $100M, to advance its oral therapy candidate VIM0423 into Phase 2 trials for dystonia and Parkinson’s disease.
  • XCath (Houston, TX, USA) raised $30M in Series C funding to advance development and commercialization of its neuro-endovascular surgical robotics platform. 
  • MAX BioPharma (Los Angeles, CA, USA) raised $13M in Series A funding to initiate and complete a Phase 1a/1b first-in-human study of its oxysterol drug candidate Oxy210 for metabolic dysfunction-associated steatohepatitis (MASH).
  • May Health (Menlo Park, CA, USA) raised $11.7M in funding to support its pivotal U.S. IDE trial for the Anavi System and prepare for European launch of its treatment for PCOS-related infertility.
  • Casma Therapeutics (Cambridge, MA, USA) received $7.6M in Michael J. Fox Foundation grants to support biomarker development and IND-enabling studies for its TRPML1 agonist CSM-101 for Parkinson’s disease
  • MindImmune (Providence, RI, USA) received a $5M Alzheimer’s Drug Discovery Foundation grant to advance development of its immune-targeting Alzheimer’s therapy candidate MITI-101 and support translational studies and IND submission.
  • Linnaeus Therapeutics (Haddonfield, NJ, USA) raised $4.5M in Series B funding to initiate a clinical trial of its GPER-targeting therapy for melanoma and expand its research team. 
  • Amydis (San Diego, CA, USA) received a $2.5M National Institutes of Health grant to advance development of an ocular tracer test to detect the neurodegenerative biomarker TDP-43 associated with ALS and related diseases. 
  • BIOCAPTIVA (Edinburgh, United Kingdom) raised $2M in funding to advance its magnetic bead technology for capturing cell-free DNA from blood samples to improve liquid biopsy cancer diagnostics and expand its product portfolio. 
  • SignaCor Therapeutics (Belfast, United Kingdom) raised $312K in Seed funding to advance development of a therapeutic designed to repair heart damage and treat hypertrophic cardiomyopathy. 
  • Earendil Labs (Wilmington, DE, USA) raised $787M in funding to scale its AI-driven platform for biologics discovery and advance its therapeutic pipeline. 
  • Crossbow Therapeutics (Cambridge, MA, USA) raised $77M in Series B funding to advance clinical development of its TCR-mimetic antibody therapies, including completion of a Phase 1 trial for CBX-250 and progression of additional oncology programs. 
  • VST BIO (San Diego, CA, USA) raised $45M in Series A funding to advance its lead stroke therapy into first-in-human studies and expand its development platform. 
  • Unnatural Products (Santa Cruz, CA, USA) raised $45M in Series B funding to advance its macrocyclic peptide therapeutics pipeline and expand its drug discovery platform targeting undruggable diseases
  • Mestag Therapeutics (London, United Kingdom) raised $40M in funding to support a Phase 1 clinical trial of its lead oncology antibody program and advance its pipeline in cancer and inflammatory diseases. 
  • Congruence Therapeutics (Montreal, Canada) raised $39.5M in funding to advance its pipeline of small molecule correctors, including a Phase 1/1b clinical trial for genetic obesity and additional programs targeting Parkinson’s disease and alpha-1 antitrypsin deficiency. 
  • Spectral AI (Dallas, TX, USA) received a $31.7M BARDA grant to advance development and additional features of its AI-driven DeepView® burn wound imaging system. 
  • Kupando (Schönefeld, Germany) raised $10M in Series A funding to support a Phase 1b clinical trial of its lead candidate KUP101 in advanced solid tumors and to advance preclinical infectious disease programs. 
  • Carecubes (Arden Hills, MN, USA) raised $6.5M in Series A funding to expand deployment of its isolation units designed to prevent infectious disease transmission in healthcare settings. 
  • Surf Therapeutics (Austin, TX, USA) raised $6M in seed funding to advance development of its non-invasive ultrasound neuromodulation therapies targeting immune-related pathways. 
  • Ternary Therapeutics (London, United Kingdom) raised $4.4M in Seed funding to advance its AI-driven platform for designing molecular glue therapeutics targeting previously undruggable proteins. 
  • HEARTio (Pittsburgh, PA, USA) raised $4.25M in Seed funding to support clinical studies and pursue FDA clearance for its AI-based cardiac diagnostic platform. 
  • Scinus (Utrecht, Netherlands) raised $3.2M in funding to support the global rollout of its bioreactor platform for scalable cell therapy manufacturing. 
  • SK bioscience (Incheon, South Korea) received a $3M RIGHT Foundation grant to advance a Phase 1b clinical trial of its RSV preventive monoclonal antibody candidate RSM01 in infants. 
  • Mave Health (San Francisco, CA, USA) raised $2.1M in seed funding to launch a wearable headset designed to improve focus, mood, and stress regulation. 
  • Daré Bioscience (San Diego, CA, USA) received a $2M NIH grant to advance development of its intravaginal ring therapy for the prevention of preterm birth. 
  • Myomaker Bio (London, United Kingdom) raised $400K in pre-Seed funding to advance its lab-grown human muscle platform for improving drug testing and early-stage research. 
  • Artelo Biosciences (Solana Beach, CA, USA) received a grant from Glaucoma UK and the HSC R&D Division to support a clinical study evaluating ART27.13 in patients with glaucoma and ocular hypertension.
  • Pinnacle Medicines (Shanghai, China) raised $89M in Series B funding to advance its oral peptide therapeutics pipeline into clinical proof-of-concept studies and further develop its AI-enabled discovery platform. 
  • Immutrin (Cambridge, United Kingdom) raised $87M in Series A funding to advance its antibody therapy for ATTR amyloidosis through clinical proof of concept, aiming to remove existing amyloid deposits and improve disease outcomes. 
  • Gilgamesh Pharma (New York, NY, USA) raised $60M in Series A funding to advance its pipeline of neuropsychiatric therapies, including late-stage development of its lead candidate for major depressive disorder. 
  • Terrestrial Bio (Cambridge, MA, USA) raised $50M in Series C funding to advance its microneedle patch platform for delivery of GLP-1 therapies. 
  • Endogenex (Minneapolis, MN, USA) raised $50M in Series C funding to support its pivotal clinical study and advance its duodenum-targeting treatment for type 2 diabetes toward FDA approval. 
  • EpiFrontier Therapeutics (Pennington, NJ, USA) received up to $32M Japan Agency for Medical Research and Development grant to advance clinical development of its G9a inhibitor EPF-001 for sickle cell disease and beta thalassemia. 
  • Amani Therapeutics (NewYork, NY, USA) raised $25M in Series A funding to advance its lead neuropsychiatric therapy AM-01, a combination treatment designed to improve the safety profile of clozapine for schizophrenia patients. 
  • Laigo Bio (Utrecht, Netherlands) raised $18M in seed funding to advance its SureTACs™ targeted protein degradation platform across oncology and autoimmune disease programs. 
  • Cellbricks Therapeutics (Berlin, Germany) raised $11M in seed funding to advance its biofabricated tissue implants toward clinical development for soft tissue repair and regenerative medicine. 
  • RyboDyn (San Diego, CA, USA) raised $10M in seed funding to advance its AI-driven platform for discovering novel cancer targets from the dark proteome. 
  • Virchow Medical (La Jolla, CA, USA) raised $4M in seed funding to advance its biopsy specimen biorepository platform and expand access to precision oncology diagnostics. 
  • Aptadel Therapeutics (Barcelona, Spain) raised $2.2M in bridge funding to advance development of its RNA-based therapy for Ewing’s sarcoma toward clinical trials. 
  • Myosin Therapeutics (FL, USA) received a $2M Florida Cancer Innovation Fund grant to support its Phase 1/2 STAR-GBM clinical trial evaluating MT-125 in patients with glioblastoma.
  • Secretome Therapeutics (TX, USA) received a $250K Parent Project Muscular Dystrophy grant to advance its cardiac cell therapy STM-01 for Duchenne-associated cardiomyopathy. 
  • Tessera Therapeutics (MA, USA) received a grant from the Gates Foundation to support early-stage research developing in vivo gene writing strategies aimed at enabling a scalable cure for HIV. 

 

March 2026 Emerging Biopharma Companies

  • Atrium Therapeutics (San Diego, CA, USA) launched with $270M to advance targeted RNA therapies for rare genetic cardiomyopathies, including PRKAG2 syndrome and PLN cardiomyopathy. 
  • Slate Medicines (Raleigh, NC, USA) launched with $130M in Series A funding to advance its anti-PACAP monoclonal antibody SLTE-1009 into Phase 1 clinical trials for the prevention of migraine and other headache disorders. 
  • Salma Health (San Mateo, CA, USA) emerged from stealth with $80M in Series A funding to establish integrated brain health centers that combine advanced diagnostics, rapid-acting treatments and AI-enabled care coordination under one roof. 
  • Baba (New York, NY, USA) emerged from stealth with $6.5M in Seed funding to expand its Medicare-covered patient advocacy platform supporting older adults and caregivers across their healthcare journeys. 
  • CubaseBio (Stockholm, Sweden) emerged from stealth with $6.4M in funding to commercialize its 3D spatial transcriptomics platform and scale volumetric DNA microscopy for drug discovery and disease research applications.
  • Beren Therapeutics (Thousand Oaks, CA, USA) emerged from stealth as a clinical-stage biotechnology company developing derivatized cyclodextrin-based therapeutics targeting impaired intracellular cholesterol trafficking, including programs for Niemann-Pick disease type C and other neurodegenerative disorders.
  • Prolium Bioscience (New York, NY, USA) launched with $50M in Series A funding to advance development of its CD20xCD3 T-cell engager PRO-203 for severe autoimmune diseases. 
  • Wisdom Bioscience (Orange, CA, USA) emerged from stealth with $28M in funding to develop sequencing based oral cancer screening tests for use in dental clinics to enable earlier cancer detection.
  • NexCure (Boston, MA, USA) launched with $19M in Series A funding to expand access to CAR-T and other advanced therapies by enabling delivery in community-based outpatient settings. 
  • SteerBio (Houston, TX, USA) launched with up to $18.2M in grant funding to develop a regenerative injectable therapy designed to restore damaged lymphatic vessels and treat lymphedema. 
  • Outpost Bio (London, United Kingdom) raised $3.5M in pre-seed funding to develop AI models that predict how molecules interact with the human microbiome. 
  • Forma Life Sciences (Irvine, CA, USA) launched to provide contract development and manufacturing services for oral solid dosage drug products across clinical and commercial stages. 
  • Quintessence Biotech (Paris, France) emerged from stealth to develop biomimetic bioseparation technology aimed at improving manufacturing workflows for cell and gene therapies. 
  • Persevere Therapeutics (Chesterbrook, PA, USA) emerged from stealth and raised an undisclosed seed funding round to advance development of its oncology therapy misetionamide for platinum-resistant ovarian cancer. 
  • Waiv (Paris, France) launched as a spinout from Owkin with $33M in funding to develop AI-powered precision diagnostic tests for patient stratification in clinical care and clinical trials. 
  • Tacit Therapeutics (San Francisco, CA, USA) emerged from stealth with $19M in funding to advance its splicing-directed RNA repair platform for neurological diseases including Huntington’s disease. 
  • Unreasonable Labs (Mountain View, CA, USA) emerged from stealth with $13.5M in funding to develop an AI-driven discovery engine designed to generate novel scientific hypotheses and accelerate research across chemistry, materials science, and biology. 
  • Living Models (Berkeley, CA, USA) emerged from stealth with $7M in seed funding to develop AI foundation models trained on DNA, RNA, and multi-omics data to advance biological research and crop development. 
  • Aquila Health AI (Omaha, NE, USA) emerged from stealth to launch a healthcare data integration platform designed to support cross-jurisdiction epidemiological monitoring and population health tracking. 
  • Agilent Advanced Therapeutics (Santa Clara, CA, USA) launched to unify Agilent’s CDMO capabilities across the United States and Canada for advanced therapeutic development and manufacturing. 
  • Excalipoint Therapeutics (Shanghai, China) launched with $68.7M in seed funding to develop next-generation T-cell engager therapies targeting cancer and autoimmune diseases. 
  • R1 Therapeutics (Redwood City, CA, USA) launched with $77.5M in Series A funding to advance a first-in-class therapy for hyperphosphatemia in chronic kidney disease patients and progress its lead candidate through Phase 2b development. 
  • iDEL Therapeutics (Dortmund, Germany) launched with $9M in seed funding to develop an oncology pipeline using direct cytosolic delivery technology targeting intracellular cancer mechanisms. 
  • PerturbAI (San Francisco, CA, USA) emerged from stealth to develop AI-driven therapeutics using in vivo CRISPR and causal genomics to enable scalable drug discovery. 
  • Intertwined Biosciences (Boston, MA, USA) emerged from stealth with $200K in non-dilutive support to develop an AI-driven drug discovery platform focused on diseases such as advanced liver cirrhosis. 
  • Voitheia BioScience (Dublin, Ireland) is operating in stealth to develop precision therapeutics and biomarkers for neurological diseases with a focus on female-prevalent conditions. 
  • Kalohexis (Northbrook, IL, USA) emerged from stealth to advance therapeutics targeting the melanocortin system for obesity and metabolic diseases. 
  • Origin Genomics (New York, NY, USA) launched to develop precision germline gene correction technologies aimed at preventing severe inherited diseases, with a focus on safety, regulatory compliance, and early-stage research. 
  • Oryon Cell Therapies (Belmont, MA, USA) emerged from stealth with $42M in Series A funding to advance autologous neuron replacement therapies for Parkinson’s disease and other neurodegenerative disorders. 
  • Neion Bio (New York, USA) emerged from stealth with $11M in seed funding to develop a genetic engineering platform for scalable, lower-cost production of biologic medicines using egg-based biomanufacturing systems.